Project Grant HT94252510427
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$768K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New Brunswick, NJ 08901, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a universal "off-the-shelf" macrophage-based cell therapy for pancreatic cancer treatment. The $403,687 award to Rutgers, The State University of New Jersey will fund a 2-year project to: Demonstrate the anti-tumor activities of phosphatidylserine (PS)-targeted chimeric antigen receptor (CAR) macrophages (A-PS CAR-Ms) against human pancreatic ductal...
The Defense Health Agency awarded Rutgers, The State University of New Jersey a $942,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support targeted chemotherapeutic and immunotherapeutic research for drug-resistant ovarian cancer. The three-year award beginning April 1, 2023 will fund Rutgers Biomedical and Health Sciences' investigation into medical solutions for this treatment-resistant form of ovarian cancer through innovative research...
This $835,531 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund a research project at The Johns Hopkins University to develop a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV mismatch repair-proficient (MMR-P) pancreatic ductal adenocarcinoma. The project aims to transform healthcare for military service members and the broader...
This federal Project Grant award, valued at $610,656.00 and granted by the Defense Health Agency, supports research to decipher the epigenetic mechanisms that contribute to poor responses to KRAS inhibition in lung cancer. The project is being conducted by The Trustees of Columbia University in the City of New York, Health Sciences Division, a prominent academic research institution with extensive expertise in biomedical research, public health, and federal contracting. The Military Medical...
The Institute For Cancer Research will receive $1,368,836 under a three-year Project Grant from the Department of the Army Medical Command to investigate the role of the acetyl-CoA pathway in resistance to anti-androgen therapy. Funded through the Military Medical Research and Development program (CFDA 12.420), this research aims to transform health care for service members and the public by investigating medical solutions for the battlefield and innovative biomedical research. The awardee,...
This federal Project Grant award of $336,257.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV MMR-P pancreatic ductal adenocarcinoma. The 3-year award, which runs from September 1, 2024 to August 31, 2027, is granted to The Johns Hopkins University, a private non-profit research institution...
The Sloan-Kettering Institute For Cancer Research was awarded an $883,531 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research into the dietary influence on liver metastasis in pancreatic cancer from September 30, 2022 to September 29, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
The Institute For Cancer Research, a non-profit research organization and subsidiary of Temple University, was awarded a $534,445 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer, with a project period from August 1, 2023 to July 31, 2026. The Institute For Cancer Research has extensive...
The Johns Hopkins University will receive $620,588 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research to develop a 3D multiscale analysis of malignant progression in human pancreatic cancer. Through September 2025, researchers will investigate medical solutions for pancreatic cancer at the cellular and tissue levels to transform understanding and treatment of this...
The Trustees of the University of Pennsylvania were awarded a $560,870 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from September 2021 through September 2024 to target hepatocyte-derived factors in order to improve the efficacy of immunotherapy for pancreatic cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the...